New and Emerging Treatments for Cystic Fibrosis

Drugs

Volumn 75, Issue 11, 2015, Pages 1165-1175

  Barry, Peter J ^a   Jones, Andrew M ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZTREONAM; COLISTIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GALACTOSE OLIGOSACCHARIDE; IVACAFTOR; MANNITOL; PANCREAS ENZYME; TOBRAMYCIN; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRY POWDER; G551D GENE; GENE; GENE MUTATION; GENE THERAPY; HUMAN; LUNG CLEARANCE; MUCOCILIARY CLEARANCE; MULTICENTER STUDY (TOPIC); NEBULIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); DRUG DESIGN; GENETICS; MUTATION; PATHOPHYSIOLOGY;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; HUMANS; MUTATION; QUINOLONES;

EID: 84938417802     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0424-8     Document Type: Article

References (99)

1. Stephenson AL, Mannik LA, Walsh S, et al. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr. 2013;97(4):872-7.
2. 1 in young adults with cystic fibrosis. Thorax. 2006;61(2):155-7.
3. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J. 2007;29(3):522-6.
4. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs. 2009;69(14):1903-10.
5. Riordan JR, Rommens JM, B-s Kerem, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-73.
6. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 2002;54(11):1373-93.
7. Yang Y, Li Q, Ertl H, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;69(4):2004-15.
8. Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies JC, Gill DR, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax. 2013;68(11):1075-7.
9. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2(7):539-47.
10. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci. 2009;106(44):18825-30.
11. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-72.
12. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-25.
13. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2(11):902-10.
14. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175-84.
15. Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros. 2015;14(1):84-9.
16. Hoare S, McEvoy S, McCarthy CJ, Kilcoyne A, Brady D, Gibney B, et al. Ivacaftor imaging response in cystic fibrosis. Am J Respir Crit Care Med. 2014;189(4):484.
17. Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D. Ivacaftor improves appearance of sinus disease on computerized tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol. 2015;40(1):16-21.
18. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013;14(6):417-21.
19. Hayes D, Warren PS, McCoy KS, Sheikh SI. Improvement in hepatic steatosis in cystic fibrosis with ivacaftor therapy. J Pediatr Gastroenterol Nutr. 2015;60(5):578-9.
20. Hayes D Jr, McCoy KS, Sheikh SI. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Respir Crit Care Med. 2014;190(4):468.
21. Grasemann H, Ratjen F, Solomon M. Aquagenic wrinkling of the palms in a patient with cystic fibrosis. N Engl J Med. 2013;369(24):2362-3.
22. Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ, et al. Effects of ivacaftor in cystic fibrosis patients carrying the G551D mutation with severe lung disease. Chest. 2014;146(1):152-8.
23. De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674-80.
24. Davies JC, Roberston S, Green Y, Rosenfeld M. An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with CF and a CFTR gating mutation: the KIWI study. Pediatr Pulmonol. 2014;49(S38):S286.
25. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718-24.
26. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. WS23.6 ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study. J Cyst Fibros. 2014;13:S44.
27. Moss R, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. S17 Effects of ivacaftor in CF patients with R117H-CFTR. Pediatr Pulmonol. 2014;49(S38):S221.
28. Nick JA, Rodman D, St Clair C, Jones MC, Li H, Higgins M, et al. Effect of ivacaftor in patients with cystic fibrosis, residual CFTR function, and FEV1 ≥40 % of predicted, N-of-1 study. Pediatr Pulmonol. 2014;49(S38):S285.
29. Goodman N, Watson K, Charlwood J, Schuhmann I, Nicholls I, Boulton C, et al. QBW251 is a novel CFTR potentiator that has been studies in healthy volunteers. Pediatr Pulmonol. 2014;49(S38):S232-3.
30. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci. 2011;108(46):18843-8.
31. Clancy J, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12-8.
32. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527-38.
33. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015 (Epub ahead of print).
34. Available from: http://investors.vrtx.com/releasedetail.cfm?releaseid=880537.
35. Cholon DM, Quinney NL, Fulcher ML, Esther CR, Das J, Dokholyan NV, et al. Potentiator ivacaftor abrogates pharmacological correction of DF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra96.
36. Veit G, Avramescu RG, Perdomo D, Phuan P-W, Bagdany M, Apaja PM, et al. Some gating potentiators, including VX-770, diminish DF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra97.
37. Donaldson S, Pilewski J, Griese M, Dong Q, Lee P-S. WS7. 3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis. J Cyst Fibros. 2013;12(S1):S14.
38. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-9.
39. Smyth AR, Bell SC, Bojcin S, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(S1):S23-42.
40. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-32.
41. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-8.
42. Cystic Fibrosis Foundation. Patient registry annual data report 2013. Bethesda: Cystic Fibrosis Foundation; 2013.
43. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10(1):54-61.
44. Schuster A, Haliburn C, Doring G, Freedom Study G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68(4):344-50.
45. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68(9):818-25.
46. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2012;185(2):171-8.
47. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011;55(6):2636-40.
48. Elborn JS, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015. doi:10.1016/j.jcf.2014.12.013.
49. Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D. tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase 1, randomized, dose-escalation study. Clin Ther. 2013;35(10):1571-81.
50. Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49(7):650-8.
51. Tullis DE, Burns JL, Retsch-Bogart GZ, Lipuma JJ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros. 2014;13(3):296-305.
52. Powell LC, Sowedan A, Khan S, et al. The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms. Biofouling. 2013;29(4):413-21.
53. Walshaw M, McElvaney G, Williams R, Morice A, Carroll M, Haworth C, et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients. J Cyst Fibros. 2014;13(S2):S58.
54. Lai HC, Fitzsimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000;342(12):851-9.
55. Eigen H, Rosenstein BJ, Fitzsimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation prednisone trial group. J Pediatr. 1995;126(4):515-23.
56. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis. Trends and physician attitudes. Chest. 1999;115(4):1053-8.
57. Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros. 2014;13(2):148-55.
58. Sagel SD. The challenges of developing effective anti-inflammatory agents in cystic fibrosis. J Cyst Fibros. 2015;14(2):164-6.
59. Calabrese C, Tosco A, Carnovale V, Basile C, Magliocca A, Quattrucc S, et al. Randomized, single-blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. J Cyst Fibros. 2015;14(2):203-10.
60. Griese M, Kappier M, Eismann C, Ballmann M, Junge S, Rietschel E, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized controlled trial. Am J Respir Crit Care Med. 2013;188(1):83-9.
61. Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros. 2015;14(2):219-27.
62. Taylor-Cousar JL, Wiley C, Felton LA, St. Clair C, Jones M, Curran-Everett D, et al. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015;14(2):228-36.
63. Fila L, Grandcourtova A, Vichova M, Valentova Bartakova L. Influence of treatment with sildenafil on lung function and exercise tolerance in cystic fibrosis adults. J Cyst Fibros. 2013;12(S1):S67.
64. Noel S, Dhooghe B, Leal T. PDE5 inhibitors as potential tools in the treatment of cystic fibrosis. Front Pharmacol. 2012;3:167.
65. Carlile GW, Robert R, Goepp J, Matthes E, Liao J, Kus B, et al. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cyst Fibros. 2015;14(1):16-25.
66. Donaldson SH, Taylor-Cousar JL, Rosenbluth D, Zeitlin P, Chmiel J, Jain M, et al. Safety, tolerability, and pharmacokinetics of the intravenous S-nitrosoglutathione reductase inhibitor N6022: an ascending-dose study in subjects homozygous for the F508Del-CFTR Mutation. Pediatr Pulmonol. 2014;49(S38):S308.
67. Shoemaker S, Madagere A, Troha J, Abbas V, Galloway C, Elhard M. Safety, tolerability, and pharmacokinetics of the oral S-nitrosoglutathione reductase inhibitor N91115: a multiple ascending-dose study in healthy subjects. Pediatr Pulmonol. 2014;49(S38):S313-4.
68. Callahan KA, Diener-West M, Schoeberlein C, Boyle MP, Zeitlin PL. Prelimionary safety profile of digitoxin to treat CF. Pediatr Pulmonol. 2014;49(S38):S293.
69. Springmann EB, Grosswald R, Philpot E, MacGregor G, Horsley A, Bilton D, et al. A phase 1 clinical trial of CTX-4430 in cystic fibrosis patients. Pediatr Pulmonol. 2014;49(S38):S311.
70. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros. 2013;12(3):241-8.
71. Rocca J, Manin S, Hulin A, Pruliere-Excabasse C, Verbecq-Morlot W, Wohlhuter-Haddad A, et al. Sulindac, a new use for an old drug in CF: CFTR potentiator and COX-independent antiinflammatory effects. Pediatr Pulmonol. 2014;49(S38):S304.
72. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42.
73. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241-50.
74. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229-40.
75. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, et al. Inhaled hypertonic saline in infants and children less than six years of age with cystic fibrosis: the ISIS randomized trial. J Am Med Assoc. 2012;307(21):2269-71.
76. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 2011;38(5):1071-80.
77. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012;185(6):645-52.
78. Deterding R, Retsch-Bogart G, Milgram L, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005;39(4):339-48.
79. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 2007;176(4):362-9.
80. Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med. 2011;183(5):627-34.
81. Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):539-49.
82. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013;162(4):676-80.
83. Zeitlin PL, Boyle MP, Guggino WB, et al. A phase I trial of intranasal Moli 1901 for cystic fibrosis. Chest. 2004;125(1):143-9.
84. O'Riordan TG, Donn KH, Hodsman P, et al. hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv. 2014;27(3):200-8.
85. Borowitz D, Stevens C, Brettman LR, et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 2011;10(6):443-52.
86. Borowitz D, Stevens C, Brettman LR, et al. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. J Pediatr Gastroenterol Nutr. 2012;54(2):248-57.
87. VanDevanter DR. How will we evaluate multiple inhaled antibiotic efficacy or effectiveness? Pediatr Pulmonol. 2014;49(S38):164-5.
88. Barry PJ, Jones AM, Webb AK, Horsley AR. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Thorax. 2014;69(6):586-7.
89. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013;143(1):14-8.
90. Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros. 2013;12(6):706-13.
91. Konstan MW, Plant BJ, Elborn JS, Rodriguez S, Munck A, Ahrens R, et al. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis. Pediatr Pulmonol. 2015;50(5):447-55.
92. Sawicki GS, Ren CL, Konstan MW, Millar SJ, Pasta DJ, Quittner AL, et al. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros. 2013;12(5):461-7.
93. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012;47(6):523-33.
94. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91-6.
95. Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142-51.
96. Siracusa C, Clancy JP, Drotar D. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. Pediatr Pulmonol. 2014;49(S38):440.
97. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):177-85.
98. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014;11(3):342-50.
99. Bush A, Simmonds NJ. Hot off the breath: 'I've a cost for' - the 64 million dollar question. Thorax. 2012;67(5):382-4.